Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...
Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, ...
In a move expected to benefit thousands of New Jersey residents living with obesity and type 2 diabetes, Novo Nordisk, whose U.S. headquarters is based in Plainsboro, announced it will significantly ...
The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone injection, according to a press release issued by Novo Nordisk.Somapacitan-beco ...
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for ...
O6, Mike Wilson, Morgan Stanley CIO and chief U.S. equity strategist, appeared on CNBC’s ‘Squawk Box’ to talk about the latest market trends and the state of the economy.
Novo Nordisk received approval from the Food and Drug Administration for three new indications of Sogroya, a growth hormone.
Novo Nordisk’s post-trial sell-off may be overdone. Click here for this comparative analysis of NVO and LLY stocks and see ...
On Feb. 5, the Trump administration launched TrumpRx, a new digital platform designed to help Americans navigate the often-crushing costs of prescription drugs. While President Trump has called the ...
Generate Biomedicines Inc. raised proceeds of $400 million from its initial public offering, the largest biotech IPO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results